此乃要件 請即處理 閣下如 對本通函任何方面或應採取的行動 有任何疑問，應諮詢閣下的股票經紀 或其他持牌證券交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓 名下全部 南京維立志博生物科技股份有限公司 股 份，應 立 即將本通函連同代表委任表格送交買方或承讓人，或送交經手買賣或轉讓的銀行、 股票經紀或其他代理人，以便轉交買方或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Nanjing Leads Biolabs Co., Ltd. 南京維立志博生物科技股份有限公司 （於中華人民共和國成立的股份有限公司） 臨時股東會會議適用的代表委任表格於香港交易所網站（www.hkexnews.hk）及 本 公司網站（www.leadsbiolabs.com）刊 載。倘 閣 下 擬 委 任 受 委 代 表 出 席 臨 時 股 東 會 會議，務請按印列的指示儘快填妥代表委任表格，且無論如何不遲於臨時股東會 會議或其任何續會指定舉行時 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （於 中 華 人 民 共 和 國 成 立 的 股 份 有 限 公 司） （股 份 代 號：9887） 公 告 Nanjing Leads Biolabs Co., Ltd. 南 京 維 立志博生物科技股份有限公司 南 京 維 立志博生物科技股份有限公司（「本公司」）董事會（「董事會」）謹 此 宣 布， 本公司擬於2025年12月17日（星 期 三）舉行臨時股東會會議（「臨時股東會會議」）。 本公司將於2025年12月12日（星 期 五）至2025年12月17日（星 期 三）（包 括 首 尾 兩 日） 期間暫停辦理本公司H股（「H股」）過 戶 登 記 手 續，期 間 將 不 會 辦 理H股 過 戶。為 符 合 資 格 出 席 臨 時 股 東 會 會 議 並 於 會 上 投 票，H股持有人須於2025年12月11日 （星 期 四）下 午 四 時 三 十 ...

格隆汇11月25日丨维立志博-B(09887.HK)宣布，于2025年11月25日审议批准建议采纳H股奖励计划以及 建议取消监事会及建议修改章程。 ...

智通财经APP讯，维立志博-B(09887)发布公告，于2025年11月25日审议批准建议采纳H股奖励计划。H 股奖励计划旨在：促进实现公司长远可持续发展及业绩目标;把受让人的利益与股东、投资者及公司的 利益紧密联系起来，从而增强公司凝聚力，促进公司实现最大价值;及完善公司激励机制，以吸引、激 励及留聘对公司持续经营、发展及长远增长贡献良多的集团董事、高级管理层及雇员。 ...

维立志博-B(09887)发布公告，于2025年11月25日审议批准建议采纳H股奖励计划。H股奖励计划旨在： 促进实现公司长远可持续发展及业绩目标;把受让人的利益与股东、投资者及公司的利益紧密联系起 来，从而增强公司凝聚力，促进公司实现最大价值;及完善公司激励机制，以吸引、激励及留聘对公司 持续经营、发展及长远增长贡献良多的集团董事、高级管理层及雇员。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Nanjing Leads Biolabs Co., Ltd. 南 京 維 立志博生物科技股份有限公司 （於 中 華 人 民 共 和 國 成 立 的 股 份 有 限 公 司） （股 份 代 號：9887） (1)建議採納H股 獎 勵 計 劃；及 (2)建議取消監事會及建議修改章程 南 京 維 立志博生物科技股份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）董事會（「董事會」）謹 此 宣 布，於2025年11月25日審議批准建議採納H股獎勵 計 劃 以 及 建 議 取 消 監 事 會 及 建 議 修 改 章 程。 (1) 建議採納H股獎勵計劃 H股 獎 勵 計 劃 的 主 要 條 款 概 述 如 下： 1. H股獎勵計劃的目的 2. 期 限 除董事會可根據H股獎勵計劃規則（「計劃規則」）決 定 提 前 終 止 外，H股 獎勵 ...

Summary of Key Points Core Viewpoint - As of November 21, 14 stocks reached their 52-week highs, with Hengfa Optical (01134), Chaowei Holdings (08059), and Cassava Resources (00841) leading the gains at 42.11%, 30.56%, and 22.49% respectively [1]. 52-Week Highs - Hengfa Optical (01134) closed at 0.375, with a peak price of 0.540, marking a 42.11% increase [1]. - Chaowei Holdings (08059) closed at 0.030, reaching a high of 0.047, reflecting a 30.56% rise [1]. - Cassava Resources (00841) closed at 0.200, with a maximum price of 0.207, indicating a 22.49% increase [1]. - Other notable stocks include Sibor Systems (08319) at 15.04%, MOS HOUSE (01653) at 11.46%, and Tianjin Jianfa (02515) at 5.19% [1]. 52-Week Lows - China Pengfei Group (03348) reached a low of 1.100, down 20.09% from its peak [1]. - China Information Technology (08178) closed at 0.285, reflecting a 19.35% decrease [1]. - XL Ernan Strategy - U (09799) saw a decline of 14.27% [1]. - Other significant declines include Hesai - W (02525) at -10.54% and MBC Bitcoin - U (03425) at -9.09% [1]. Additional Notable Stocks - Stocks like MBC Bitcoin (03430) and Tongyuan Kang Pharmaceutical - B (02410) also experienced declines of 6.64% and 6.62% respectively [2]. - The overall trend indicates a mix of significant gains in certain stocks while others are facing substantial losses, reflecting a volatile market environment [1][2].

Group 1 - The core viewpoint of the articles highlights the strong performance of innovative drug stocks in the market, with notable increases in share prices for companies such as Gilead Sciences-B (up 8.82%) and Kintor Pharmaceutical (up 4.60%) [1] - The report from CICC emphasizes the importance of innovative drugs and medical devices in China's "14th Five-Year Plan," indicating a shift from "follow-up innovation" to "quality transformation" in domestic innovative drugs [1] - The collaboration between Hansoh Pharmaceutical and Roche for the global exclusive license of the antibody-drug conjugate HS-20110 is seen as a significant advancement, with expectations for smooth development due to Roche's expertise [2] Group 2 - The partnership between Innovent Biologics and Takeda Pharmaceutical aims to advance the development of next-generation tumor immunotherapy and antibody-drug conjugates, leveraging Takeda's strong sales network in Japan and the West [2] - Valiant Pharmaceuticals' agreement with the U.S. company Dianthus for the development and commercialization of its autoimmune drug LBL-047 outside Greater China is viewed as beneficial for product development [2] - The overall sentiment in the pharmaceutical industry is optimistic regarding the international expansion of innovative drugs, with multiple companies securing significant partnerships to enhance their research and commercialization efforts [2]

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The report highlights the promising advancements in the company's product pipeline, particularly LBL-034 and LBL-024, which are positioned to redefine treatment paradigms in multiple myeloma and other cancers [3][4] - The company has a strong financial position with sufficient cash reserves to support multiple research pipelines, bolstered by recent fundraising efforts [6] - Revenue projections indicate a gradual increase, with expected revenues of 260 million in 2025, 284 million in 2026, and 467 million in 2027, reflecting a growth rate of 64% in 2027 [5][6] Summary by Sections Product Development - LBL-034 has shown a 90.9% overall response rate (ORR) in a specific dosage group for treating relapsed/refractory multiple myeloma, demonstrating "Best-in-class" potential compared to competitors [3] - LBL-024 has effectively addressed liver toxicity issues associated with 4-1BB agonists, with a reported ≥3 grade liver enzyme elevation of only 1.3% across approximately 450 enrolled patients [4] - Initial clinical data for LBL-024 in non-small cell lung cancer (NSCLC) shows an ORR of 50% and a disease control rate (DCR) of 94.4%, indicating significant therapeutic potential [4] Financial Projections - The company is projected to have total revenues of 260 million, 284 million, and 467 million from 2025 to 2027, with year-over-year growth rates of 9% and 64% respectively [5] - The net profit attributable to the parent company is expected to be -416 million, -518 million, and -719 million for the same period, with a declining growth rate [5][6] - The gross margin is anticipated to be 100% in 2025 and 2026, decreasing to 93.68% in 2027 [5] Cash Position - As of the first half of 2025, the company had cash and cash equivalents of 422 million, supplemented by net proceeds of 1.363 billion HKD from its initial public offering [6]

Core Viewpoint - The announcement by Valiant Biopharma-B (09887) regarding the successful administration of the first patient in the Phase II clinical trial of LBL-024 for first-line treatment of hepatocellular carcinoma marks significant progress in expanding the indications for this core product [1] Group 1: Clinical Trial Details - The Phase II clinical study is an open-label, multi-center trial led by Professor Zhou Jian from Zhongshan Hospital affiliated with Fudan University, currently being conducted in multiple hospitals across the country [1] - The trial aims to evaluate the efficacy and safety of the combination therapy using Opalizumab (PD-L1/4-1BB bispecific antibody LBL-024) for patients with hepatocellular carcinoma [1] Group 2: Product Information - LBL-024 is a bispecific antibody targeting both PD-L1 and 4-1BB, representing the first targeted therapy for the 4-1BB receptor to reach the registered clinical stage for treating extra-pulmonary neuroendocrine carcinoma [1] - LBL-024 is expected to become the first approved drug for the treatment of advanced extra-pulmonary neuroendocrine carcinoma [1] - Utilizing the proprietary X-body platform, LBL-024 features an optimal 2:2 structural design that can relieve PD-1/L1 immune suppression and enhance 4-1BB-mediated T cell activation, achieving a synergistic effect in tumor elimination, demonstrating greater potential for broad-spectrum cancer treatment compared to PD-1/L1 inhibitors [1]